{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:32:54Z","timestamp":1788449574382,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"abbvie, inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In previous clinical trials, patients with active rheumatoid arthritis (RA) treated with upadacitinib (UPA) have improved patient-reported outcomes (PROs). This post hoc analysis of SELECT-CHOICE, a phase 3 clinical trial, evaluated the impact of UPA vs abatacept (ABA) with background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on PROs in patients with RA with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients in SELECT-CHOICE received UPA (oral 15 mg\/day) or ABA (intravenous). PROs evaluated included Patient Global Assessment of Disease Activity (PtGA) by visual analog scale (VAS), patient\u2019s assessment of pain by VAS, Health Assessment Questionnaire Disability Index (HAQ-DI), morning stiffness duration and severity, 36-Item Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Productivity and Activity Impairment (WPAI), and EQ-5D 5-Level (EQ-5D-5L) index score. Least squares mean (LSM) changes from baseline to weeks 12 and 24 were based on an analysis of covariance model. Proportions of patients reporting improvements \u2265 minimal clinically important differences (MCID) were compared using chi-square tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 612 patients were analyzed (UPA, <jats:italic>n<\/jats:italic>=303; ABA, <jats:italic>n<\/jats:italic>=309). Mean age was 56 years and mean disease duration was 12 years. One-third received \u22652 prior bDMARDs and 72% received concomitant methotrexate at baseline. At week 12, UPA- vs ABA-treated patients had significantly greater improvements in PtGA, pain, HAQ-DI, morning stiffness severity, EQ-5D-5L, 2\/4 WPAI domains, and 3\/8 SF-36 domains and Physical Component Summary (PCS) scores (<jats:italic>P<\/jats:italic>&lt;0.05); significant differences persisted at week 24 for HAQ-DI, morning stiffness severity, SF-36 PCS and bodily pain domain, and WPAI activity impairment domain. At week 12, significantly more UPA- vs ABA-treated patients reported improvements \u2265MCID in HAQ-DI (74% vs 64%) and SF-36 PCS (79% vs 66%) and 4\/8 domain scores (<jats:italic>P<\/jats:italic>&lt;0.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>At week 12, UPA vs ABA treatment elicited greater improvements in key domains of physical functioning, pain, and general health and earlier improvements in HAQ-DI. Overall, more UPA- vs ABA-treated patients achieved \u2265MCID in most PROs at all timepoints; however, not all differences were statistically significant. These data, however, highlight the faster response to UPA treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03086343\">NCT03086343<\/jats:ext-link>, March 22, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02813-x","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T11:07:09Z","timestamp":1656068829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Martin","family":"Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Tundia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Suboticki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayeshkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"issue":"5","key":"2813_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685\u201395.","journal-title":"Rheumatol Int"},{"issue":"3 Suppl 59","key":"2813_CR2","first-page":"S32","volume":"28","author":"V Strand","year":"2010","unstructured":"Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S32\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2813_CR3","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar4491","volume":"16","author":"H Radner","year":"2014","unstructured":"Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16(1):R56.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2813_CR4","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/ar2951","volume":"12","author":"T Sokka","year":"2010","unstructured":"Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010;12(2):R42.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2813_CR5","first-page":"1241","volume":"34","author":"T Uhlig","year":"2007","unstructured":"Uhlig T, Loge JH, Kristiansen IS, Kvien TK. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"2813_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2813_CR7","doi-asserted-by":"publisher","first-page":"e0193489","DOI":"10.1371\/journal.pone.0193489","volume":"13","author":"Q Shi","year":"2018","unstructured":"Shi Q, Li KJ, Treuer T, Wang BCM, Gaich CL, Lee CH, et al. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD). PLoS One. 2018;13(4):e0193489.","journal-title":"PLoS One"},{"issue":"1","key":"2813_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","volume":"20","author":"JC Sergeant","year":"2018","unstructured":"Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM, et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther. 2018;20(1):147.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2813_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12955-018-1035-3","volume":"16","author":"A Gibofsky","year":"2018","unstructured":"Gibofsky A, Galloway J, Kekow J, Zerbini C, de la Vega M, Lee G, et al. Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. Health Qual Life Outcomes. 2018;16(1):211.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2813_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/acr.20685","volume":"64","author":"NA Khan","year":"2012","unstructured":"Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res. 2012;64(2):206\u201314.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"2813_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11914-018-0473-5","volume":"16","author":"A Zhang","year":"2018","unstructured":"Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep. 2018;16(5):603\u201310.","journal-title":"Curr Osteoporos Rep"},{"issue":"10","key":"2813_CR12","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/rheumatology\/kew241","volume":"55","author":"KL Druce","year":"2016","unstructured":"Druce KL, Bhattacharya Y, Jones GT, Macfarlane GJ, Basu N. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2016;55(10):1786\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2813_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-019-2037-1","volume":"21","author":"V Strand","year":"2019","unstructured":"Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21(1):272.","journal-title":"Arthritis Res Ther"},{"key":"2813_CR14","doi-asserted-by":"crossref","unstructured":"Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song IH, et al. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford). 2021;60(12):5583\u201394.","DOI":"10.1093\/rheumatology\/keab158"},{"issue":"1","key":"2813_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13075-019-2059-8","volume":"21","author":"V Strand","year":"2019","unstructured":"Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263.","journal-title":"Arthritis Res Ther"},{"issue":"10188","key":"2813_CR16","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311.","journal-title":"Lancet."},{"issue":"3","key":"2813_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.clinthera.2008.03.002","volume":"30","author":"EM Massarotti","year":"2008","unstructured":"Massarotti EM. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis. Clin Ther. 2008;30(3):429\u201342.","journal-title":"Clin Ther"},{"issue":"7","key":"2813_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/acr.22763","volume":"68","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, et al. Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res. 2016;68(7):907\u201313.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"2813_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, et al. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules. 2020;10(7):1002.","journal-title":"Biomolecules."},{"issue":"5","key":"2813_CR20","first-page":"Cd012183","volume":"2016","author":"JA Singh","year":"2016","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochr Database Syst Rev. 2016;2016(5):Cd012183.","journal-title":"Cochr Database Syst Rev"},{"issue":"12","key":"2813_CR21","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.clinthera.2016.11.004","volume":"38","author":"M-C Vieira","year":"2016","unstructured":"Vieira M-C, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clin Ther. 2016;38(12):2628\u201341.e5.","journal-title":"Clin Ther"},{"key":"2813_CR22","doi-asserted-by":"publisher","first-page":"8417249","DOI":"10.1155\/2017\/8417249","volume":"2017","author":"E Bergrath","year":"2017","unstructured":"Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. Int J Rheumatol. 2017;2017:8417249.","journal-title":"Int J Rheumatol"},{"issue":"16","key":"2813_CR23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"2813_CR24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3899\/jrheum.110392","volume":"38","author":"V Strand","year":"2011","unstructured":"Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38(8):1720\u20137.","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"2813_CR25","first-page":"Abstract 2268","volume":"65","author":"H Kitchen","year":"2013","unstructured":"Kitchen H, B H, L A. Patient-reported outcome measures for rheumatoid arthritis: Minimal important differences review. Arthritis Rheum. 2013;65(Suppl 10):Abstract 2268.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2813_CR26","first-page":"2016","volume":"32","author":"GA Wells","year":"2005","unstructured":"Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: A preliminary definition. J Rheumatol. 2005;32(10):2016\u201324.","journal-title":"J Rheumatol"},{"issue":"Suppl 39","key":"2813_CR27","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(Suppl 39):S14\u2013S8.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2813_CR28","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811\u20139.","journal-title":"J Rheumatol"},{"issue":"10","key":"2813_CR29","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"11","key":"2813_CR30","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/acr.22374","volume":"66","author":"AM Orbai","year":"2014","unstructured":"Orbai AM, Smith KC, Bartlett SJ, De Leon E, Bingham CO 3rd. \"Stiffness has different meanings, I think, to everyone\": examining stiffness from the perspective of people living with rheumatoid arthritis. Arthritis Care Res. 2014;66(11):1662\u201372.","journal-title":"Arthritis Care Res"},{"issue":"Suppl 11","key":"2813_CR31","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1002\/acr.20633","volume":"63","author":"K Tang","year":"2011","unstructured":"Tang K, Beaton DE, Boonen A, Gignac MA, Bombardier C. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res. 2011;63(Suppl 11):S337\u201349.","journal-title":"Arthritis Care Res"},{"issue":"Suppl 11","key":"2813_CR32","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.1002\/acr.20541","volume":"63","author":"L Busija","year":"2011","unstructured":"Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res. 2011;63(Suppl 11):S383\u2013412.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"2813_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"key":"2813_CR34","doi-asserted-by":"crossref","unstructured":"Lauck SB, Lewis KB, Borregaard B, de Sousa I. \"What Is the Right Decision for Me?\" Integrating Patient Perspectives Through Shared Decision-Making for Valvular Heart Disease Therapy. Can J Cardiol. 2021;37(7):1054\u201363.","DOI":"10.1016\/j.cjca.2021.02.022"},{"issue":"4","key":"2813_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1586\/eci.12.23","volume":"8","author":"BJ van den Bemt","year":"2012","unstructured":"van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337\u201351.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2813_CR36","first-page":"269","volume":"4","author":"J Jin","year":"2008","unstructured":"Jin J, Sklar GE, Min Sen OV, Chuen LS. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269\u201386.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2813_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.24428","volume":"61","author":"F Wolfe","year":"2009","unstructured":"Wolfe F, Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum. 2009;61(5):667\u201373.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2813_CR38","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/art.23002","volume":"57","author":"D Lacaille","year":"2007","unstructured":"Lacaille D, White MA, Backman CL, Gignac MAM. Problems faced at work due to inflammatory arthritis: New insights gained from understanding patients' perspective. Arthritis Care Res. 2007;57(7):1269\u201379.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"2813_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1185\/03007990902774765","volume":"25","author":"DE Stull","year":"2009","unstructured":"Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 11","key":"2813_CR40","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/acr.20621","volume":"63","author":"JK Anderson","year":"2011","unstructured":"Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res. 2011;63(Suppl 11):S14\u201336.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2813_CR41","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.20048","volume":"50","author":"E Krishnan","year":"2004","unstructured":"Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50(3):953\u201360.","journal-title":"Arthritis Rheum"},{"key":"2813_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2015-208329","volume":"75","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Gladman DD, Edwards CJ, Poder A, Liote F, Bird P, et al. THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. Ann Rheum Dis. 2016;75:1.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2813_CR43","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.socscimed.2004.08.034","volume":"60","author":"CA Marra","year":"2005","unstructured":"Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571\u201382.","journal-title":"Soc Sci Med"},{"issue":"2","key":"2813_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11136-013-0498-2","volume":"23","author":"A Hinz","year":"2014","unstructured":"Hinz A, Kohlmann T, Stobel-Richter Y, Zenger M, Brahler E. The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. Qual Life Res. 2014;23(2):443\u20137.","journal-title":"Qual Life Res"}],"updated-by":[{"DOI":"10.1186\/s13075-022-02940-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000}}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02813-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T12:07:23Z","timestamp":1667650043000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02813-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2813"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02813-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13075-022-02940-5","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13075-022-02940-5","URL":"https:\/\/doi.org\/10.1186\/s13075-022-02940-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by an independent ethics committees or institutional review board at all study sites. All participants provided written informed consent prior to enrollment. The registered clinical trial was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and is consistent with the International Conference on Harmonization Good Clinical Practice and Good Epidemiology Practices, and all applicable local regulatory requirements. All patient data were de-identified and complied with patient confidentiality requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB is a consultant\/speaker for AbbVie, Amgen, BMS, Genentech\/Roche, Gilead, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi\/Regeneron; and shareholder of Johnson & Johnson (parent company of Janssen).GCW has received speaker and consulting fees from AbbVie and BMS.NM, JLS, and JP are employees and stockholders of AbbVie.NT is a former employee of AbbVie and may hold stock.DG and YS are employees of Analysis Group, Inc., which received consulting fees from AbbVie for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}